根据研究生院《关于开展2024年度“圣和研究生创新成果奖”评选工作的通知》规定，经个人申报、学院审核及专家评审等程序，评定马越等8名同学获得国际医药商学院2024年度“圣和研究生创新成果奖”，现将获奖名单予以公示。公示时间自2024年11月11日至15日，公示期内对获选名单有异议者，可向学院书面提出意见。联系人：刘老师，联系电话：86185036。
中国药科大学国际医药商学院
2024年11月11日
附：国际医药商学院2024年度“圣和研究生创新成果奖”获选名单
序号 | 姓名 | 学号 | 学科专业 | 发表论文题目 | 发表期刊 | 获奖等级 | 奖金金额 |
1 | 马越 | 3122044198 | 药物经济学 | An Economic Evaluation of Family-Based Versus Traditional Helicobacter pylori Screen-and-Treat Strategy:Based on Real-World Data and Microsimulation Model | Helicobacter | 二等奖 | 2000 |
2 | 邵翰乔 | 3222041174 | 药物经济学 | A network meta-analysis of efcacy and safety for frst-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer | BMC Medicine | 三等奖 | 1000 |
3 | 万楚川 | 3122044193 | 社会与管理药学 | Health utility of patients with established rheumatoid arthritis and its influencing factors: a multi-center study in China | SCIENTIFIC REPORTS | 三等奖 | 1000 |
4 | 武宇航 | 3222041177 | 药物经济学 | Efficacy, Safety, and Immunogenicity of Subunit Respiratory Syncytial Virus Vaccines: Systematic Review and Meta-Analysis of Randomized Controlled Trials | Vaccines | 三等奖 | 1000 |
5 | 丁瑞琳 | 3122044182 | 社会与管理药学 | Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment | The Patient - Patient-Centered Outcomes Research | 三等奖 | 1000 |
6 | 蒙文鑫 | 3322041279 | 药学（管理药学） | Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective | BMC Public Health | 三等奖 | 1000 |
7 | 李艳 | 3122045013 | 药物经济学 | Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports | European Journal of Health Economics | 三等奖 | 1000 |
8 | 高翔 | 3222041130 | 社会与管理药学 | Investigation on pharmaceutical care barriers perceived by clinical pharmacists in secondary and tertiary hospitals in China | HELIYON | 三等奖 | 1000 |
